Journal of Peking University(Health Sciences) >
Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement
Received date: 2021-08-05
Online published: 2021-12-13
Supported by
National Natural Science Foundation of China(81801617);National Natural Science Foundation of China(81771678);National Natural Science Foundation of China(81971520);Research and Development Fund of Peking University People’s Hospital(RDX2020-03)
Objective: To investigate the clinical and immunological features of cardiac involvement in patients with anti-synthetase syndrome (ASS). Methods: In the study, 96 patients diagnosed with ASS hospitalized in the Department of Rheumatology and Immunology, Peking University People’s Hospital from April 2003 to November 2020 were included. The patients were divided into two groups according to whether they were accompanied with cardiac involvement. Demographic features, clinical characteristics (Gottron’s sign/papules, muscle damage, etc.), comorbidities, laboratory indices (creatine kinase, inflammatory indicators, immunoglobulin, complement, lymphocyte subset, autoantibodies, etc.) were collected and the differences between the two groups were analyzed statistically. Results: The prevalence of cardiac involvement in the patients with ASS was 25.0% (24/96). The ASS patients complicated with cardiac involvement presented with elevated cardiac troponin I (cTnI, 75.0%, 18/24), pericardial effusion (33.3%, 8/24), reduction of left ventricular function (33.3%, 8/24) and valves regurgitation (33.3%, 8/24). The age of onset of the patients with cardiac involvement was older than that of the patients without cardiac involvement [(54.58±10.58) years vs. (48.47±13.22) years, P=0.043). Arthritis was observed less frequently in the patients with cardiac involvement than those without cardiac involvement (37.5% vs. 61.1%, P=0.044). In addition, rapidly progressive interstitial lung disease (54.2% vs. 30.6%, P=0.037) was observed more frequently in the patients with cardiac involvement than those without cardiac involvement. As compared with the ASS patients without cardiac involvement, C-reactive protein (CRP) [(13.55 (8.96, 38.35) mg/L vs. 4.60 (1.37, 17.40) mg/L, P=0.001], and lactate dehydrogenase (LDH) [408.0 (255.0, 587.0) U/L vs. 259.5 (189.8, 393.8) U/L, P=0.007] were significantly higher in the patients with cardiac involvement. Anti-Ro-52 antibody was detected more commonly in the ASS patients with cardiac involvement compared with the patients without cardiac involvement (91.7% vs. 69.4%, P=0.029). No significant differences were found in the comorbidities, alanine transaminase (ALT), aspartate transaminase (AST), creatine kinase (CK), erythrocyte sedimentation rate (ESR), ferritin (Fer), immunoglobulin G (IgG), complement 3 (C3), complement 4 (C4), lymphocyte subset between the two groups. Conclusion: Cardiac involvement is common in ASS, mainly manifested as myocardial damage. It is necessary to be aware of cardiac complications in patients with elevated CRP, elevated LDH and positive anti-Ro-52 antibody.
Key words: Anti-synthetase syndrome; Myocarditis; Myositis; Autoantibodies
Lan LUO , Xiao-yan XING , Yun-shu XIAO , Ke-yan CHEN , Feng-yun-zhi ZHU , Xue-wu ZHANG , Yu-hui LI . Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement[J]. Journal of Peking University(Health Sciences), 2021 , 53(6) : 1078 -1082 . DOI: 10.19723/j.issn.1671-167X.2021.06.012
| [1] | Jayakumar D, Zhang R, Wasserman A, et al. Cardiac manifestations in idiopathic inflammatory myopathies: An overview[J]. Cardiol Rev, 2019, 27(3):131-137. |
| [2] | Opinc AH, Makowski MA, Lukasik ZM, et al. Cardiovascular complications in patients with idiopathic inflammatory myopathies: Does heart matter in idiopathic inflammatory myopathies?[J]. Heart Fail Rev, 2021, 26(1):111-125. |
| [3] | Sharma K, Orbai AM, Desai D, et al. Brief report: Antisynthetase syndrome-associated myocarditis[J]. J Card Fail, 2014, 20(12):939-945. |
| [4] | Connors GR, Christopher-Stine L, Oddis CV, et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in the past 35 years?[J]. Chest, 2010, 138(6):1464-1474. |
| [5] | Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: An international collaborative tool to facilitate myositis research[J]. Ann Rheum Dis, 2018, 77(1):30-39. |
| [6] | Li Y, Gao X, Li Y, et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: A series of 474 patients[J]. Front Med (Lausanne), 2020, 7:363. |
| [7] | Dieval C, Deligny C, Meyer A, et al. Myocarditis in patients with antisynthetase syndrome: Prevalence, presentation, and outcomes[J]. Medicine (Baltimore), 2015, 94(26):e798. |
| [8] | Katz A, Bena J, Chatterjee S. Antisynthetase syndrome: Prevalence of serositis in autoantibody subsets [C/OL]. 2018 ACR/ARHP Annual Meeting [2021-06-17]. https://acrabstracts.org/abstract/antisynthetase-syndrome-prevalence-of-serositis-in-autoan-tibody-subsets/. |
| [9] | Ketlogetswe KS, Aoki J, Traill TA, et al. Severe aortic regurgitation secondary to antisynthetase syndrome[J]. Circulation, 2011, 124(3):e40-e41. |
| [10] | Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis[J]. Curr Rheumatol Rep, 2012, 14(3):275-285. |
| [11] | Wang H, Liu T, Cai YY, et al. Pulmonary hypertension in polymyositis[J]. Clin Rheumatol, 2015, 34(12):2105-2112. |
| [12] | Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: Clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature[J]. Medicine (Baltimore), 2012, 91(4):206-211. |
| [13] | Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody[J]. Semin Arthritis Rheum, 2012, 41(6):890-899. |
| [14] | La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease[J]. Autoimmunity, 2006, 39(3):249-253. |
| [15] | Xing X, Li A, Li C. Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis[J]. Respir Med, 2020, 172(12):106134. |
/
| 〈 |
|
〉 |